Cassava Sciences Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Consumer Staples Select Sector SPDR Fund trades at $83.47 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 342.6× Cassava Sciences Inc's market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| FLNA | XLP | |
|---|---|---|
Market Cap | $39.40M | $13.50B |
Volume | 759,018 | 14,599,953 |
Sector | Health | — |
52-Week High | $4.64 | $90.00 |
52-Week Low | $0.68 | $75.61 |
Typical Hold Time | 37 Days | 72 Days |
Enterprise Value | -$43.28M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.41, up 2.09% with bullish technical signals from moving averages and oscillators. The ETF shows strong relative performance, gaining 6.6% year-to-date while consumer discretionary stocks declined. Analyst sentiment is unanimously positive with 100% buy ratings, supported by the fund's low 0.08% expense ratio and defensive positioning during market volatility.
The outlook remains favorable given XLP's defensive characteristics amid economic uncertainty, though rising interest rates pose a headwind. The ETF's focus on household staples provides stability, with dividend income adding to total return potential. Key risks include inflation pressures and consumer spending shifts toward value-oriented options.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →